Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma

@inproceedings{Menzies2014InterAI,
  title={Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma},
  author={Alexander M. Menzies and Lauren E. Haydu and Matteo Carlino and Mary W. F. Azer and Peter J Carr and Richard F. Kefford and Georgina V Long},
  booktitle={PloS one},
  year={2014}
}
BACKGROUND MAPK inhibitors (MAPKi) are active in BRAF-mutant metastatic melanoma patients, but the extent of response and progression-free survival (PFS) is variable, and complete responses are rare. We sought to examine the patterns of response and progression in patients treated with targeted therapy. METHODS MAPKi-naïve patients treated with combined dabrafenib and trametinib had all metastases ≥5 mm (lymph nodes ≥15 mm in short axis) visible on computed tomography measured at baseline and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor dabrafenib or vemurafenib beyond disease progression

  • M Chan, L Haydu, AM Menzies, MWF Azer, O Klein
  • Journal of Clinical Oncology
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…